Biological therapies for eosinophilic asthma
- 3 July 2018
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 18 (7), 747-754
- https://doi.org/10.1080/14712598.2018.1492540
Abstract
Introduction: Severe uncontrolled asthma is by definition refractory to traditional therapies or can be controlled only with therapies that have intolerable side effects. Monoclonal antibodies that target interleukin (IL)-5/IL-5Rα, IgE, and IL-4Rα have shown favorable results in clinical trials, including reductions in asthma exacerbations and other important clinical outcomes. These biological agents offer treatment alternatives to patients with uncontrolled severe eosinophilic asthma. Areas covered: This article reviews how the shifting emphasis toward identifying distinct asthma phenotypes has led to the approval of biological therapies that preferentially benefit patients with severe eosinophilic asthma. The clinical trials that led to the approval of these biologic treatments are discussed in detail. Expert opinion: Biologic therapies targeting the IL-5, IgE, IL-4/IL-13 signaling pathways have been successful in clinical trials in subjects with severe eosinophilic asthma. Some of these agents have also been successful regardless of peripheral blood eosinophil counts. These treatments have shown a relatively favorable safety profile in clinical trials, although long-term safety data for some of these agents are limited. Due to the high costs associated with these medications, they should be reserved for select patients where they yield a therapeutic and pharmacoeconomic advantage.Keywords
This publication has 61 references indexed in Scilit:
- Anti-interleukin-5 therapy in severe asthmaEuropean Respiratory Review, 2013
- Asthma endotypes: A new approach to classification of disease entities within the asthma syndromeJournal of Allergy and Clinical Immunology, 2011
- A new look at the pathogenesis of asthmaClinical Science, 2009
- Severe asthma and the omalizumab optionClinical and Molecular Allergy, 2008
- PrefaceJournal of Allergy and Clinical Immunology, 2007
- CD2 identifies a monocyte subpopulation with immunoglobulin E‐dependent, high‐level expression of FcɛRIClinical and Experimental Allergy, 2006
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJournal of Allergy and Clinical Immunology, 2001
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.The Journal of Experimental Medicine, 1996